Cytokinetics, Incorporated Appoints Robert Wong as Vice President, Chief Accounting Officer
May 17, 2019 at 06:08 am EDT
Share
On May 15, 2019, Cytokinetics, Incorporated appointed Robert Wong as Vice President, Chief Accounting Officer. Mr. Wong was most recently Interim Chief Accounting Officer at Genentech, a division of Roche where he served for 23 years.
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.
CYTOKINETICS, INCORPORATED 
